Home Posts Tagged "X-Linked Retinitis Pigmentosa"

X-Linked Retinitis Pigmentosa

Biogen Pays $124 Million to Develop Gene-Based Therapies

Carrie Ann, July 3, 2015

Biogen Pays $124 Million to Develop Gene-Based Therapies

Featured Healthcare & Pharmaceutical Manufacturing & Retail NEWS

On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing …

Aspiring Business Leaders Worldwide

X-Linked Retinitis Pigmentosa

Biogen Pays $124 Million to Develop Gene-Based Therapies

READ THE MAGAZINE

MARCH 2020 ISSUE

BUSINESS MAGNATES
THEN & NOW

Get Connected

YOU FIRST

About Industry Leaders Magazine

Get Connected

Recent Posts

2020 Ferrari F8 Spider Review

Ford ready to launch its new Bronco family sub brands

Checklist to tick if planning on reopening your business

Uber Eats acquires Postmates for $2.65 billion

Other Navigation

Leadership Story Of The Month

Mark Cuban’s Rules for Startups and Entrepreneurs

Aspiring Business Leaders Worldwide

Biogen Pays $124 Million to Develop Gene-Based Therapies

READ THE MAGAZINE

MARCH 2020 ISSUE

BUSINESS MAGNATES THEN & NOW

Get Connected

YOU FIRST

Mark Cuban’s Rules for Startups and Entrepreneurs

Register today to get full access to:

PASSWORD RESET

Register today to get full access to:

Subscribe Plan Details

Register today to get full access to:

LOGIN

BUSINESS MAGNATES
THEN & NOW